NMPA Streamlines Cell and Gene Therapy Drug Approval to 30-Day Clinical Trial Review Window

The National Medical Products Administration (NMPA) announced recently that cell and gene therapy drugs meeting specific criteria will be placed into an expedited 30-day review pathway for clinical trial approvals. The announcement came as the NMPA's Comprehensive Department released a draft notice for public consultation on optimizing the regulatory process for cell and gene therapy pharmaceuticals.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments